methyl (2S,3R)-2,3-dihydroxypentanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: methyl (2S,3R)-2,3-dihydroxypentanoate
• 化学式: C₆H₁₂O₄
• 分子量: 148.159
• InChiKey: PMBZZBIURKJQJN-UHNVWZDZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl (2S,3R)-2,3-dihydroxypentanoate 在 咪唑 、 copper(l) iodide 、 正丁基锂 、 二异丁基氢化铝 、 碳酸氢钠 、 potassium carbonate 、 caesium carbonate 、 戴斯-马丁氧化剂 、 sodium iodide 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 34.72h， 生成 (5R,6R)-5-((1E,3E)-15-(1,3-dioxolan-2-yl)pentadeca-1,3-dien-5,8,11-triyn-1-yl)-6-ethyl-2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecane
  参考文献：
  名称：

  Total syntheses of four possible stereoisomers of resolvin E3

  摘要：

  Resolvin E3, 17,18-dihydroxy-5Z,8Z,11Z,13E,15E-eicosapentaenoic acid, is a potent anti-inflammatory lipid mediator. To determine the stereochemistries of the C17- and C18-hydroxy groups of resolvin E3 and to supply a sufficient amount of material for future biological studies, we developed a highly convergent and practical route to its four possible stereoisomers. The key reactions employed here were the Horner-Wadsworth-Emmons coupling, the two copper(I)-mediated reactions between the alkynes and the propargyl tosylates, and the simultaneous reduction of the three triple bonds to the three Z-olefins. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2012.02.045
• 作为产物：
  描述：

  反-2-戊酸甲酯 在 四氧化锇 、 甲基磺酰胺 、 水 、 potassium carbonate 、 氢化奎尼定 1,4-(2,3-二氮杂萘)二醚 、 potassium hexacyanoferrate(III) 作用下， 以 叔丁醇 为溶剂， 反应 24.0h， 以58%的产率得到methyl (2S,3R)-2,3-dihydroxypentanoate
  参考文献：
  名称：

  Total syntheses of four possible stereoisomers of resolvin E3

  摘要：

  Resolvin E3, 17,18-dihydroxy-5Z,8Z,11Z,13E,15E-eicosapentaenoic acid, is a potent anti-inflammatory lipid mediator. To determine the stereochemistries of the C17- and C18-hydroxy groups of resolvin E3 and to supply a sufficient amount of material for future biological studies, we developed a highly convergent and practical route to its four possible stereoisomers. The key reactions employed here were the Horner-Wadsworth-Emmons coupling, the two copper(I)-mediated reactions between the alkynes and the propargyl tosylates, and the simultaneous reduction of the three triple bonds to the three Z-olefins. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2012.02.045

文献信息

• Total synthesis of four stereoisomers of (5Z,8Z,10E,14Z)-12-hydroxy-17,18-epoxy-5,8,10,14-eicosatetraenoic acid and their anti-inflammatory activities
  作者：Tomomi Goto、Daisuke Urabe、Yosuke Isobe、Makoto Arita、Masayuki Inoue

  DOI：10.1016/j.tet.2015.08.047

  日期：2015.10

  The four stereoisomers of novel lipid mediator 1, (5Z,8Z,10E,14Z)-12-hydroxy-17,18-epoxy-5,8,10,14-eicosatetraenoic acid, were synthesized from six simple fragments. Triyne 2 was convergently assembled through three SN2 alkynylation reactions and one Sonogashira coupling reaction. Two of the three alkynes of 2 were hydrogenated using Lindlar catalyst, while the third alkyne was reduced through formation

  的四种立体异构体新的脂质介体1，（5 Ž，8 Ž，10 ê，14 Ž）-12-羟基17,18环氧5,8,10,14二十碳四烯酸，分别从六个简单片段合成。Triyne 2被会聚通过三个S组装Ñ 2炔基化反应和一个Sonogashira偶联反应。三个炔烃的两个2用Lindlar催化剂将其氢化，同时通过形成炔-二钴六羰基配合物并随后还原分解来还原第三种炔，以立体选择性的方式产生所需的四烯结构。接着，在C1两步官能团操作，接着通过同时脱保护和环氧化物的形成，产生了四种异构体，（12小号，17 - [R，18小号） - 1AA，（12小号，17小号，18 - [R ）- 1AB，（12 - [R，17 - [R，18小号） - 1BA和（12 - [R，17小号，18[R ）- 1BB。本工作允许测定天然存在的绝对结构的1是1AA和1AB，以及两个天然（生物评价1AA，1AB）和两个非天然（1BA，
• Asymmetric synthesis of (−)-α-conhydrine
  作者：Subba Rao V. Kandula、Pradeep Kumar

  DOI：10.1016/j.tetasy.2005.08.045

  日期：2005.10

  The enantioselective synthesis of (−)-α-conhydrine has been achieved by two different synthetic routes. The key steps include Sharpless asymmetric dihydroxylation, regioselective opening of a cyclic sulfate and Wittig olefination.

  （-）-α-conhydrine的对映选择性合成已通过两种不同的合成途径实现。关键步骤包括Sharpless不对称二羟基化，环状硫酸盐的区域选择性开环和Wittig烯烃化。
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：BARRY CLIFTON

  公开号：WO2011087995A2

  公开（公告）日：2011-07-21

  This invention provides compounds which are useful in the treatment of mycobacterial infections, pharmaceutical compositions containing the compounds, processes for their preparation, and uses of the compounds in various medicinal applications, such as the treatment or prevention of mycobacterial infections, such as those caused by Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium leprae, Mycobacterium africanum, Mycobacterium avium, Mycobacterium microti, or any mycobacterium that causes multi-drug resistant (MDR) TB or extensively resistant (XDR) TB, or any other mycobacterial species known to cause disease in humans; or the treatment or prevention of parasitic diseases, such as those caused by a parasite of the genus Trypanosoma, e.g. Trypanosoma cruzi or Trypanosoma brucei or a parasite of the genus Leishmania which causes visceral leishmaniasis or kala-azar, e.g., Leishmania donovani.